ArticleCurrent genomics2013
Parkinson's disease: from genetics to clinical practice.
Article in Current genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Eukaryotic translation initiation factorExperimental and therapeutic medicine · 2024Article
- Serum metabolomic characterization of PLA2G6-associated dystonia-parkinsonism: A case-control biomarker study.Frontiers in neuroscience · 2022Article
- Targeted next-generation sequencing identifies novel variants in candidate genes for Parkinson's disease in Black South African and Nigerian patients.BMC medical genetics · 2020Article
- Variants in the 3' End of SLC6A3 in Northwest Han Population with Parkinson's.Parkinson's disease · 2019Article
- Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing.Molecular genetics & genomic medicine · 2018Article
- Identification of therapeutic targets for Parkinson's disease via bioinformatics analysis.Molecular medicine reports · 2017Article
- Mutation Analysis of Consanguineous Moroccan Patients with Parkinson's Disease Combining Microarray and Gene Panel.Frontiers in neurology · 2017Article
- Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?Frontiers in aging neuroscience · 2017Review
- Mitochondrial Biology and Neurological Diseases.Current neuropharmacology · 2016Review
- Inflammation in Parkinson's disease: role of glucocorticoids.Frontiers in neuroanatomy · 2015Review
- Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review.Journal of Parkinson's disease · 2015Review
- Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease.North American journal of medical sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthroughs in genetics over the last decade have radically advanced our understanding of the etiological basis of Parkinson's disease (PD). Although much research remains to be done, the main genetic causes of this neurodegenerative disorder are now partially unraveled, allowing us to feel more confident that our knowledge about the genetic architecture of PD will continue to increase exponentially. How and when these discoveries will be introduced into general clinical practice, however, remains uncertain. In this review, we provide a general summary of the progress in the genetics of PD and discuss how this knowledge will contribute to the diagnosis and clinical management of patients with, or at risk of this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.